The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
Study Details
Study Description
Brief Summary
The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Reproxalap Ophthalmic Solution (0.25%) QID
|
Drug: Reproxalap Ophthalmic Solution (0.25%) QID
Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
|
Placebo Comparator: Vehicle Ophthalmic Solution QID
|
Drug: Vehicle Ophthalmic Solution QID
Vehicle Ophthalmic Solution administered QID for twelve weeks
|
Experimental: Reproxalap Ophthalmic Solution (0.25%) QID to BID
|
Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID
Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
|
Placebo Comparator: Vehicle Ophthalmic Solution QID to BID
|
Drug: Vehicle Ophthalmic Solution QID to BID
Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
|
Outcome Measures
Primary Outcome Measures
- Subject-reported ocular dryness score (0 - 100 VAS) [Efficacy assessment period (Week 2 through Week 12)]
The method of assessment is subject-reported ocular dryness score (0 - 100 VAS)
- Fluorescein nasal region score (Ora Calibra® scale) [Efficacy assessment period (Week 2 through Week 12)]
The method of assessment is Fluorescein nasal region score (Ora Calibra® scale)
Secondary Outcome Measures
- Fluorescein staining [Efficacy assessment period (Week 2 through Week 12)]
The method of assessment for this outcome is the Fluorescein staining Ora Calibra®
- Unanesthetized Schirmer's Test [Efficacy assessment period (Week 2 through Week 12)]
The method of assessment for this outcome is the Schirmer test strip.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Be at least 18 years of age of either gender and any race;
-
Have a reported history of dry eye for at least 6 months prior to Visit 1;
-
Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1
Exclusion Criteria:
-
Have any clinically significant slit-lamp findings at Visit 1, including active blepharitis; meibomian gland dysfunction (MGD); lid margin inflammation; or active ocular allergies that require therapeutic treatment, or, in the opinion of the investigator may interfere with the assessment of the safety or efficacy of reproxalap or vehicle;
-
Have or be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1;
-
Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
-
Have used any eye drops within 2 hours of Visit 1;
-
Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
-
Have used ophthalmic cyclosporine or lifitigrast 5.0% ophthalmic solution within 90 days of Visit 1;
-
Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
-
Have used temporary or permanent punctal plugs within 30 days prior to Visit 1 or anticipate their use during the study period
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Eye Research Foundation | Newport Beach | California | United States | 92663 |
Sponsors and Collaborators
- Aldeyra Therapeutics, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ADX-102-DED-012